10-Q: Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics reported its financial results for the third quarter of 2024, highlighting progress in its cell therapy programs and ongoing collaborations.

Summary

• Lineage Cell Therapeutics reported a net loss of $3.0 million for the three months ended September 30, 2024, and a net loss of $15.3 million for the nine months ended September 30, 2024.
• The company's total revenue for the three months ended September 30, 2024, was $3.8 million, and $6.6 million for the nine months ended September 30, 2024.
• Collaboration revenues were $3.4 million for the quarter and $5.7 million for the nine months, primarily from the Roche agreement.
• Research and development expenses were $3.2 million for the quarter and $9.0 million for the nine months.
• General and administrative expenses were $4.4 million for the quarter and $13.8 million for the nine months.
• As of September 30, 2024, Lineage had $32.7 million in cash, cash equivalents, and marketable securities.
• The company believes its current resources will fund operations for at least the next twelve months.
• Lineage is developing cell therapies for various conditions, including geographic atrophy (GA), spinal cord injury (SCI), hearing loss, and vision loss.
• The company's lead program, OpRegen, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
• Lineage is planning to commence enrolling the DOSED study for OPC1 as soon as feasible after submitting updates to the FDA.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the RMAT designation and progress in collaborations, the company continues to incur losses and faces delays in its clinical programs. The ongoing war in Israel also adds a layer of uncertainty.

Positives

• Collaboration revenues increased significantly for the three months ended September 30, 2024, compared to the same period in the prior year.
• OpRegen received RMAT designation from the FDA, which could expedite its development and approval.
• The company has sufficient cash to fund operations for at least the next twelve months.
• Lineage is actively engaging with the FDA to advance the DOSED study for OPC1.
• The company has a diverse pipeline of cell therapy programs targeting various unmet medical needs.

Negatives

• Lineage reported a net loss of $3.0 million for the three months ended September 30, 2024, and a net loss of $15.3 million for the nine months ended September 30, 2024.
• Research and development expenses remain significant, reflecting the company's ongoing investment in its programs.
• The FDA review of the IND amendment for OPC1 is still ongoing, causing a delay in the start of the DOSED study.
• The company has incurred significant operating losses since inception and expects to continue to do so for the foreseeable future.

Risks

• The ongoing Israel-Hamas war could materially and adversely impact Lineage's operations, as its manufacturing facility is located in Jerusalem.
• The company's ability to raise additional capital may be adversely impacted by unfavorable global economic conditions.
• The company's financial obligations include future payments to licensors and government entities, which are contingent and uncertain.
• The company is subject to legal proceedings and claims in the ordinary course of business, which could have a material adverse effect on its business.
• The company's success depends on the successful development and commercialization of its product candidates, which is subject to significant risks and uncertainties.

Future Outlook

Lineage believes its current cash, cash equivalents, and marketable securities, along with projected cash flows, will be sufficient to fund operations for at least the next twelve months. The company plans to submit an additional amendment to the IND for OPC1 by the end of the year and anticipates FDA review completion in Q1 2025. Lineage also plans to commence enrolling the DOSED study for OPC1 as soon as feasible after submitting these updates.

Management Comments

• Based on that discussion we plan to submit an additional amendment to the IND and final protocol with clarifying information to the FDA by the end of the year.
• We currently anticipate that the FDA will complete its review of this amendment in Q1 2025 and we do not expect any further feedback or additional information requests that would delay start of the study.
• We currently plan to commence enrolling the DOSED study as soon as feasible after submitting these updates.

Industry Context

The announcement highlights Lineage's progress in the competitive cell therapy space, particularly with the RMAT designation for OpRegen, which could provide a significant advantage. The company's focus on allogeneic cell therapies aligns with the industry trend towards off-the-shelf treatments. The ongoing collaboration with Roche and Genentech positions Lineage as a key player in the development of cell therapies for ocular disorders.

Comparison to Industry Standards

• Lineage's collaboration with Roche is comparable to other major biotech partnerships in the cell therapy field, such as Vertex's collaboration with CRISPR Therapeutics.
• The RMAT designation for OpRegen is similar to other expedited regulatory pathways used by companies like bluebird bio and BioMarin to accelerate the development of their therapies.
• Lineage's focus on allogeneic cell therapies is in line with the industry's move away from autologous therapies, which are more complex and costly to manufacture.
• The company's cash position of $32.7 million is relatively modest compared to larger biotech companies, but it is sufficient to fund operations for at least the next twelve months.
• The company's net loss of $15.3 million for the nine months ended September 30, 2024, is typical for a clinical-stage biotech company, but it highlights the need for continued funding.

Legal Proceedings

• The company is involved in a legal proceeding related to a motion for disclosure of documents by HBL Hadasit Bio-Holdings Ltd. regarding the validity of an intercompany agreement.

Related Party Transactions

• Lineage incurred approximately $626,000 in legal expenses on behalf of Neal Bradsher, Broadwood Partners, L.P., and Broadwood Capital, Inc. related to a shareholder class action lawsuit.
• Broadwood Partners, L.P. purchased 6,730,770 common shares and Don Bailey purchased 96,155 shares in a registered direct offering.

Stakeholder Impact

• Shareholders may be concerned about the company's ongoing losses and the delay in the OPC1 clinical program.
• Employees may be affected by the ongoing war in Israel and the potential for disruptions to operations.
• Customers and partners may be impacted by any delays in the development of Lineage's product candidates.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• Lineage plans to submit an additional amendment to the IND for OPC1 by the end of the year.
• The company anticipates FDA review completion of the OPC1 IND amendment in Q1 2025.
• Lineage plans to commence enrolling the DOSED study for OPC1 as soon as feasible after submitting updates to the FDA.
• The company will continue to advance its other cell therapy programs, including ANP1 and PNC1.

Key Dates

Keywords

cell therapy, OpRegen, OPC1, RMAT designation, clinical trials, regenerative medicine, geographic atrophy, spinal cord injury, biotechnology, FDA, collaboration, Roche, financial results